Aurobindo Pharma receives US nod for anti-migraine tabletsIllustrative image – not actual.

Drug maker Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co's Maxalt Tablets of equivalent dose and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

At present, the company has a total of 171 abbreviated new drug application (ANDA) approvals from USFDA.

Source: Business Standard


 

← All latest storiesBack to top →